Metagenomi Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Metagenomi Therapeutics, Inc. (MGX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.27M, a 29.59% decline year-over-year.
- Metagenomi Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.55M, a 12.84% decline year-over-year.
- Metagenomi Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.01M, a 6.61% decline year-over-year.
- Metagenomi Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.22M, a 28.61% decline year-over-year.
- Metagenomi Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $11.85M, a 26.85% decline from fiscal 2024.
- Metagenomi Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $16.20M, a 134.09% increase from fiscal 2023.
- Metagenomi Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $6.92M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.27M 10-Q · filed 2026-08-10 | $4.82M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $2.55M 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $11.85M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $3.01M 10-Q · filed 2025-11-12 | $6.23M derived: sum of 2 quarters · filed 2026-08-10 | $9.16M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-06-30 | $3.22M 10-Q · filed 2026-08-10 | $6.15M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $2.93M 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $16.20M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $3.22M 10-Q · filed 2025-11-12 | $7.74M derived: sum of 2 quarters · filed 2025-11-12 | $12.79M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $4.51M 10-Q · filed 2025-11-12 | $9.57M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $5.06M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $6.92M 10-K · filed 2025-03-17 | |||
| 2023-09-30 | $3.27K 10-Q · filed 2024-11-13 | $659.27K derived: sum of 2 quarters · filed 2024-11-13 | $1.19M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $656.00K 10-Q · filed 2024-11-13 | $1.19M derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $529.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |